Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (+0.40%) is trading higher today, outperforming the S&P 500 (-0.44%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Jaguar Animal Health (<strong>JAGX</strong> +54.72%) enters agreement with Eli Lilly (LLY) to license, develop, and commercialize Canalevia</li><li>Aeterna Zentaris (<strong>AEZS</strong> +24.08%) completed Zoptrex pivotal phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017</li><li>Momenta Pharma (<strong>MNTA</strong> +21%) announces a US District Court ruling against Teva (TEVA) that 'further bolsters our confidence in the potential for us to offer multiple sclerosis patients a more affordable generic version of COPAXONE 40 mg following regulatory approval'</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Tenax Therapeutics (<strong>TENX</strong> -76.35%) announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints</li><li>Dimension Therapeutics (<strong>DMTX</strong> -49.41%) announces preliminary topline safety and early efficacy results of the multi-center phase 1/2 study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B</li><li>ViewRay (<strong>VRAY</strong> -8.17%) files for $75 mln mixed securities shelf offering</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>AmerisourceBergen (<strong>ABC</strong> +3.9%) beats by $0.13, misses on revs; raises FY17 EPS, reaffirms FY17 rev guidance</li><li>Thermo Fisher (<strong>TMO</strong> +4.6%) guides FY17 adj. EPS of $9.06-9.24 vs $9.14 Capital IQ Consensus Estimate; sees revs $19.38-19.62 bln vs $19.56 bln Capital IQ Consensus Estimate</li><li>Zimmer Biomet (<strong>ZBH</strong> +2.18%) beats by $0.03, reports revs in-line; guides FY17 EPS in-line, revs in-line</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>Corcept Therapeutics (<strong>CORT</strong> -4.05%) reports EPS in-line, beats on revs; guides FY17 revs in-line</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Surgery Partners (<strong>SGRY</strong> +0.83%) The Benchmark Company Initiated Coverage: BUY — Price Target: 24</li><li>Dicerna Pharma (<strong>DRNA</strong> -1.54%) resumed with a Mkt Perform at Leerink Partners</li></ul>"